Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP NYSE:MBX NYSE:PRME NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$9.37-5.4%$8.78$4.64▼$61.72$114.83M3.08100,000 shs87,032 shsMBXMBX Biosciences$15.09+5.7%$13.06$4.81▼$27.50$506.93MN/A324,882 shs154,165 shsPRMEPrime Medicine$3.24-5.8%$3.69$1.11▼$5.17$436.02M2.392.53 million shs3.03 million shsPRTAProthena$8.20-0.5%$7.14$4.32▼$22.83$441.41M-0.041.18 million shs903,119 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%-4.29%+0.64%+27.66%-84.68%MBXMBX Biosciences0.00%+5.30%+9.75%+14.84%+1,508,999,900.00%PRMEPrime Medicine0.00%-8.73%-19.80%+172.27%-24.30%PRTAProthena0.00%-6.50%+20.41%+75.97%-63.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals4.2664 of 5 stars3.63.00.04.72.81.70.6MBXMBX Biosciences2.1655 of 5 stars3.50.00.00.02.11.70.6PRMEPrime Medicine2.5986 of 5 stars3.41.00.00.01.45.00.6PRTAProthena3.6969 of 5 stars4.24.00.00.02.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$49.00422.95% UpsideMBXMBX Biosciences 3.00Buy$37.63149.34% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.92175.21% UpsidePRTAProthena 2.33Hold$22.00168.29% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, PRME, PRTA, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$81.00 ➝ $15.008/28/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.008/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.008/5/2025PRTAProthenaRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $10.008/5/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.008/5/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$28.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/APRMEPrime Medicine$4.96M87.89N/AN/A$1.37 per share2.36PRTAProthena$135.16M3.27N/AN/A$9.05 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/APRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/APRTAProthena-$122.31M-$5.64N/AN/AN/A-2,929.30%-62.17%-54.43%11/11/2025 (Estimated)Latest CRBP, PRME, PRTA, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/A8/4/2025Q2 2025PRTAProthena-$1.11-$1.86-$0.75-$2.34$5.36 million$4.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/APRMEPrime Medicine$1.4544.63%N/AN/A N/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A9.219.21MBXMBX BiosciencesN/AN/AN/APRMEPrime MedicineN/A6.506.50PRTAProthenaN/A5.685.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%MBXMBX BiosciencesN/APRMEPrime Medicine70.37%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%MBXMBX Biosciences52.19%PRMEPrime Medicine22.74%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.26 million11.77 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/APRMEPrime Medicine234134.57 million100.38 millionOptionablePRTAProthena13053.83 million48.88 millionOptionableCRBP, PRME, PRTA, and MBX HeadlinesRecent News About These CompaniesNuveen LLC Acquires Shares of 149,961 Prothena Corporation plc $PRTASeptember 1 at 3:32 AM | marketbeat.comSiren L.L.C. Raises Stake in Prothena Corporation plc $PRTAAugust 31 at 6:29 AM | marketbeat.comPiper Sandler Cuts Prothena (NASDAQ:PRTA) Price Target to $15.00August 31 at 2:40 AM | americanbankingnews.comPiper Sandler Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock PriceAugust 30 at 10:57 AM | marketbeat.comProthena's (PRTA) Buy Rating Reiterated at Chardan CapitalAugust 30 at 8:20 AM | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Holdings in Prothena Corporation plc $PRTAAugust 30 at 4:22 AM | marketbeat.comProthena provides mixed update on PRX012August 30 at 3:38 AM | thepharmaletter.comTChardan Capital Reaffirms Buy Rating for Prothena (NASDAQ:PRTA)August 30 at 2:05 AM | americanbankingnews.comProthena Corporation plc: Prothena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | finanznachrichten.deProthena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | businesswire.comProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical ProgramAugust 27, 2025 | businesswire.comWellington Management Group LLP Acquires 68,652 Shares of Prothena Corporation plc $PRTAAugust 25, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Passes Below 200 Day Moving Average - Time to Sell?August 24, 2025 | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from AnalystsAugust 15, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?August 14, 2025 | marketbeat.comCitizens JMP Remains a Buy on Prothena (PRTA)August 9, 2025 | theglobeandmail.comFY2026 EPS Estimates for Prothena Lifted by Chardan CapitalAugust 9, 2025 | marketbeat.comCantor Fitzgerald Increases Earnings Estimates for ProthenaAugust 8, 2025 | marketbeat.comFY2025 EPS Estimates for Prothena Reduced by HC WainwrightAugust 8, 2025 | marketbeat.comNovo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns HopefulAugust 7, 2025 | msn.comProthena (NASDAQ:PRTA) Price Target Cut to $10.00 by Analysts at Royal Bank Of CanadaAugust 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, PRME, PRTA, and MBX Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$9.37 -0.53 (-5.35%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.36 0.00 (-0.05%) As of 08/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.MBX Biosciences NYSE:MBX$15.09 +0.82 (+5.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.04 -0.05 (-0.33%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Prime Medicine NYSE:PRME$3.24 -0.20 (-5.81%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.29 +0.05 (+1.54%) As of 08/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Prothena NASDAQ:PRTA$8.20 -0.04 (-0.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.16 -0.04 (-0.43%) As of 08/29/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
